Heron Therapeutics, Inc. (LON:0J4V)

Market Cap	265.10M
Revenue (ttm)	115.25M
Net Income (ttm)	-10.85M
Shares Out	n/a
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	900
Average Volume	18,650
Open	2.385
Previous Close	2.320
Day's Range	2.359 - 2.385
52-Week Range	0.542 - 3.195
Beta	1.40
RSI	58.98
Earnings Date	May 9, 2025

About Heron Therapeutics

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emeto...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 122
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J4V

Financial Performance

In 2024, Heron Therapeutics's revenue was $144.29 million, an increase of 13.57% compared to the previous year's $127.04 million. Losses were -$13.58 million, -87.72% less than in 2023.

Financial numbers in USD